On Tuesday, Shares of AT&T, Inc. (NYSE:T), gained 0.69% to $35.12.
AT&T Inc., declared recently that the company’s second-quarter 2015 results will be released after the New York Stock Exchange closes on Thursday, July 23, 2015. At 4:30 p.m. ET the same day, AT&T will host a conference call to talk about the results. The company’s earnings release, Investor Briefing and related materials will be accessible at AT&T Investor Relations before the conference call starts.
AT&T Inc. provides telecommunications services in the United States and internationally. The company operates through two segments, Wireless and Wireline. The Wireless segment offers data and voice services, counting local, long-distance, and network access services, in addition to roaming services to youth, family, professionals, small businesses, government, and business customers.
Shares of Amazon.com Inc. (NASDAQ:AMZN), inclined 2.20% to $465.57, during its last trading session, hitting its highest level.
Amazon.com - Starting Wednesday, July 15, just after midnight PT, Prime members can shop thousands of exclusive lightning deals with new deals added as often as every ten minutes throughout the day. With more deals than Black Friday, members will enjoy thousands of deals from sought-after devices and tools to popular toys and pet supplies. Anyone can join Prime, to start a free 30-day trial and take part in Prime Day visit amazon.com/primeday.
Amazon.com, Inc. operates as an online retailer in North America and internationally. It operates in two segments, North America and International. The company serves consumers through retail Websites, such as amazon.com and amazon.ca, which primarily comprise merchandise and content purchased for resale from vendors and those offered by third-party sellers.
Finally, Qiagen NV (NASDAQ:QGEN), ended its last trade with 0.84% gain, and closed at $26.45, hitting its highest level.
QIAGEN, received U.S. marketing (PMA) approval of its therascreen® EGFR RGQ PCR Kit (therascreen EGFR test) as a companion diagnostic to guide the use of AstraZeneca’s IRESSA® (gefitinib) in the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). QIAGEN’s therascreen EGFR test was approved by the Food and Drug Administration to enable doctors to identify NSCLC patients who have tumors that are positive for epidermal growth factor receptor (EGFR) mutations and therefore are eligible for treatment with AstraZeneca’s drug.
More than 200,000 new lung cancer cases are diagnosed every year in the United States, with NSCLC accounting for about 85% of cases, leading to an estimated 160,000 deaths. Testing for EGFR mutations is believed to be the largest segment in companion diagnostics for personalized medicine.
QIAGEN N.V. provides sample to insight solutions that transform biological samples into valuable molecular insights worldwide. It offers sample technologies to isolate, purify, and stabilize nucleic acids and proteins in plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technologies to detect molecular targets.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
